Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 2/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14091013 | 0.91 | ITGB3 (0.38) | ITGB3ITGA2BALOX5PDPK1CASP1 | |
| SCHEMBL4425979 | 0.87 | PADI1 (0.40) | PDPK1C3AR1EPHX2 | |
| SCHEMBL4991622 | 0.87 | C3AR1 (0.45) | PDPK1C3AR1 | |
| SCHEMBL4566055 | 0.87 | C3AR1 (0.45) | PDPK1C3AR1 | |
| SCHEMBL4990654 | 0.84 | C3AR1 (0.45) | PDPK1C3AR1 | |
| SCHEMBL14090906 | 0.83 | CA1 (0.39) | PDPK1C3AR1 | |
| SCHEMBL14091012 | 0.83 | PDPK1 (0.35) | ALOX5PDPK1CASP1 | |
| SCHEMBL4992633 | 0.82 | C3AR1 (0.42) | PDPK1C3AR1EPHX2 | |
| SCHEMBL4986529 | 0.80 | C3AR1 (0.43) | PDPK1C3AR1 | |
| SCHEMBL4989197 | 0.78 | C3AR1 (0.41) | PDPK1C3AR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | ITGB3 364/4885ITGA2B 464/4885ALOX5 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.